These observations suggest that miR-30c expression is often reduced at early stages of tumor progression when decreased FHIT expression is already apparent and therefore represents one of the driving forces for early stage lung tumor cells to proceed with EMT and subsequent metastatic progression, thus highlighting the relationship between FHIT and miR-30c as potential targets for early therapeutic intervention in lung cancer progression. The gene discussed is FHIT; the disease is lung carcinoma.